GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists have significantly impacted the treatment of type 2 diabetes and obesity. Gastrointestinal adverse events represent a primary limitation of these therapies, frequently leading to discontinuation. This expert review synthesizes data from randomized controlled trials, observational studies, meta-analyses, and pharmacovigilance information to detail the incidence, mechanisms, and clinical implications of these events across various agents.
Gastrointestinal Adverse Events
Nausea, vomiting, diarrhea, and constipation are common, occurring in approximately 30%-50% of patients, particularly during initiation and dose adjustments. These events are generally mild to moderate and can be managed through dose titration and dietary changes. Mechanisms include delayed gastric emptying, activation of emetic pathways, altered intestinal motility, and the physiological effects of rapid weight loss. Acute pancreatitis has been observed, but randomized trial data do not demonstrate a class-level excess risk. Pharmacovigilance signals are most likely due to diagnostic misclassification rather than a causal relationship. Cholelithiasis shows a probable association, largely mediated by weight loss. Peri-procedural data indicate increased residual gastric volume without confirmed aspiration events.
Emerging Agents and Future Directions
Preliminary data on pipeline agents – retatrutide, survodutide, and cagrilintide-semaglutide – suggest a similar GI adverse event profile to currently approved therapies, though evidence remains limited. A proactive, patient-centered approach is recommended to optimize adherence, safety, and clinical outcomes with these expanding therapeutic options.